CNS Pharmaceuticals Inc. [NASDAQ: CNSP] traded at a low on 01/27/21, posting a -12.21 loss after which it closed the day’ session at $1.87. The company report on January 13, 2021 that InvestorBrandNetwork Announces C3 Chat Show Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco.
via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, announces that John Climaco, Chairman and CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), was recently interviewed on the C3 Chat Show Podcast, a series that addresses topics related to entrepreneurship, life experiences and best practices from experts.
The podcast, co-hosted by Sid Vaidya and Eric Gershey, is available for on-demand listening at https://anchor.fm/c3chat.
The results of the trading session contributed to over 2215250 shares changing hands. Over the past one week, the price volatility of CNS Pharmaceuticals Inc. stands at 10.21% while the volatility over the past one month is 7.72%.
The market cap for CNSP stock reached $42.80 million, with 16.48 million shares outstanding and 13.04 million shares in the current float. Compared to the average trading volume of 1.46M shares, CNSP reached a trading volume of 2215250 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about CNS Pharmaceuticals Inc. [CNSP]?
Ladenburg Thalmann have made an estimate for CNS Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 28, 2020. While these analysts kept the previous recommendation, Ladenburg Thalmann raised their target price to Buy. The new note on the price target was released on August 24, 2020, representing the official price target for CNS Pharmaceuticals Inc. stock.
The Average True Range (ATR) for CNS Pharmaceuticals Inc. is set at 0.22 The Price to Book ratio for the last quarter was 12.47, with the Price to Cash per share for the same quarter was set at 0.06.
How has CNSP stock performed recently?
CNS Pharmaceuticals Inc. [CNSP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.59. With this latest performance, CNSP shares gained by 5.06% in over the last four-week period, additionally sinking by -2.85% over the last 6 months – not to mention a drop of -52.17% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CNSP stock in for the last two-week period is set at 44.68, with the RSI for the last a single of trading hit 42.50, and the three-weeks RSI is set at 45.85 for CNS Pharmaceuticals Inc. [CNSP]. The present Moving Average for the last 50 days of trading for this stock 2.1164, while it was recorded at 2.0500 for the last single week of trading, and 2.1574 for the last 200 days.
CNS Pharmaceuticals Inc. [CNSP]: Deeper insight into the fundamentals
Return on Total Capital for CNSP is now -104.03, given the latest momentum, and Return on Invested Capital for the company is -109.96. Return on Equity for this stock declined to -109.96, with Return on Assets sitting at -90.22.
Reflecting on the efficiency of the workforce at the company, CNS Pharmaceuticals Inc. [CNSP] managed to generate an average of -$775,442 per employee.CNS Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.90 and a Current Ratio set at 4.90.
Earnings analysis for CNS Pharmaceuticals Inc. [CNSP]
With the latest financial reports released by the company, CNS Pharmaceuticals Inc. posted -0.17/share EPS, while the average EPS was predicted by analysts to be reported at -0.03/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -466.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CNSP.
Insider trade positions for CNS Pharmaceuticals Inc. [CNSP]
There are presently around $0 million, or 0.70% of CNSP stock, in the hands of institutional investors. The top three institutional holders of CNSP stocks are: ESSEX INVESTMENT MANAGEMENT CO LLC with ownership of 61,563, which is approximately -13.472% of the company’s market cap and around 0.60% of the total institutional ownership; MORGAN STANLEY, holding 12,500 shares of the stock with an approximate value of $27000.0 in CNSP stocks shares; and INTEGRATED ADVISORS NETWORK LLC, currently with $23000.0 in CNSP stock with ownership of nearly 0% of the company’s market capitalization.
Positions in CNS Pharmaceuticals Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 4 institutional holders increased their position in CNS Pharmaceuticals Inc. [NASDAQ:CNSP] by around 21,236 shares. Additionally, 3 investors decreased positions by around 10,561 shares, while 5 investors held positions by with 72,697 shares. The mentioned changes placed institutional holdings at 104,494 shares, according to the latest SEC report filing. CNSP stock had 2 new institutional investments in for a total of 16,460 shares, while 2 institutional investors sold positions of 976 shares during the same period.